"Designing Growth Strategies is in our DNA"

U.S. Diabetes Drugs Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors, and Others), By Diabetes Type (Type 1 and Type 2), By Route of Administration (Oral, Subcutaneous, and Intravenous), By Distribution Channel (Online Pharmacies, Hospital Pharmacies, and Retail Pharmacies), and Country Forecast, 2023-2030

Last Updated: December 01, 2025 | Format: PDF | Report ID: FBI109115

 

We will customize the report to meet your research goals, helping you gain a competitive edge, and make informed decisions.

  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
    4. Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
    4. Market Trends
  4. Key Insights
    1. Prevalence of Diabetes, by Type, for Key Countries / Region, 2022
    2. Pipeline Analysis, by Key Players
    3. New Product Launches, by Key Players
    4. Key Industry Developments Such as Mergers, Acquisitions, and Collaborations
    5. Impact of COVID-19 on U.S. Diabetes Drugs Market
  5. U.S. Diabetes Drugs Market Analysis, Insights and Forecast, 2019-2030
    1. Market Analysis, Insights and Forecast – By Drug Class
      1. Insulin
      2. DPP-4 Inhibitors
      3. GLP-1 Receptor Agonists
      4. SGLT2 Inhibitors
      5. Others
    2. Market Analysis, Insights and Forecast – By Diabetes Type
      1. Type-1
      2. Type-2
    3. Market Analysis, Insights and Forecast – By Route of Administration
      1. Oral
      2. Subcutaneous
      3. Intravenous
    4. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospitals Pharmacies
      2. Retail Pharmacies & Stores
      3. Online Pharmacies
  6. Competitive Analysis
    1. U.S. Market Share Analysis (2022)
    2. Company Profiles
      1. Sanofi
        1. Overview
        2. Products
        3. SWOT analysis
        4. Recent developments
        5. strategies
        6. financials (based on availability)
      2. Merck & Co., Inc.
        1. Overview
        2. Products
        3. SWOT analysis
        4. Recent developments
        5. strategies
        6. financials (based on availability)
      3. Novo Nordisk A/S
        1. Overview
        2. Products
        3. SWOT analysis
        4. Recent developments
        5. strategies
        6. financials (based on availability)
      4. Lilly
        1. Overview
        2. Products
        3. SWOT analysis
        4. Recent developments
        5. strategies
        6. financials (based on availability)
      5. AstraZeneca
        1. Overview
        2. Products
        3. SWOT analysis
        4. Recent developments
        5. strategies
        6. financials (based on availability)
      6. Takeda Pharmaceutical Company Limited
        1. Overview
        2. Products
        3. SWOT analysis
        4. Recent developments
        5. strategies
        6. financials (based on availability)
      7. Novartis AG
        1. Overview
        2. Products
        3. SWOT analysis
        4. Recent developments
        5. strategies
        6. financials (based on availability)
      8. Boehringer Ingelheim International GmbH
        1. Overview
        2. Products
        3. SWOT analysis
        4. Recent developments
        5. strategies
        6. financials (based on availability)
      9. Johnson & Johnson Services Inc.
        1. Overview
        2. Products
        3. SWOT analysis
        4. Recent developments
        5. strategies
        6. financials (based on availability)
      10. Bayer AG
        1. Overview
        2. Products
        3. SWOT analysis
        4. Recent developments
        5. strategies
        6. financials (based on availability)
  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
    4. Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
    4. Market Trends
  4. Key Insights
    1. Prevalence of Diabetes, by Type, for Key Countries / Region, 2022
    2. Pipeline Analysis, by Key Players
    3. New Product Launches, by Key Players
    4. Key Industry Developments Such as Mergers, Acquisitions, and Collaborations
    5. Impact of COVID-19 on U.S. Diabetes Drugs Market
  5. U.S. Diabetes Drugs Market Analysis, Insights and Forecast, 2019-2030
    1. Market Analysis, Insights and Forecast – By Drug Class
      1. Insulin
      2. DPP-4 Inhibitors
      3. GLP-1 Receptor Agonists
      4. SGLT2 Inhibitors
      5. Others
    2. Market Analysis, Insights and Forecast – By Diabetes Type
      1. Type-1
      2. Type-2
    3. Market Analysis, Insights and Forecast – By Route of Administration
      1. Oral
      2. Subcutaneous
      3. Intravenous
    4. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospitals Pharmacies
      2. Retail Pharmacies & Stores
      3. Online Pharmacies
  6. Competitive Analysis
    1. U.S. Market Share Analysis (2022)
    2. Company Profiles
      1. Sanofi
        1. Overview
        2. Products
        3. SWOT analysis
        4. Recent developments
        5. strategies
        6. financials (based on availability)
      2. Merck & Co., Inc.
        1. Overview
        2. Products
        3. SWOT analysis
        4. Recent developments
        5. strategies
        6. financials (based on availability)
      3. Novo Nordisk A/S
        1. Overview
        2. Products
        3. SWOT analysis
        4. Recent developments
        5. strategies
        6. financials (based on availability)
      4. Lilly
        1. Overview
        2. Products
        3. SWOT analysis
        4. Recent developments
        5. strategies
        6. financials (based on availability)
      5. AstraZeneca
        1. Overview
        2. Products
        3. SWOT analysis
        4. Recent developments
        5. strategies
        6. financials (based on availability)
      6. Takeda Pharmaceutical Company Limited
        1. Overview
        2. Products
        3. SWOT analysis
        4. Recent developments
        5. strategies
        6. financials (based on availability)
      7. Novartis AG
        1. Overview
        2. Products
        3. SWOT analysis
        4. Recent developments
        5. strategies
        6. financials (based on availability)
      8. Boehringer Ingelheim International GmbH
        1. Overview
        2. Products
        3. SWOT analysis
        4. Recent developments
        5. strategies
        6. financials (based on availability)
      9. Johnson & Johnson Services Inc.
        1. Overview
        2. Products
        3. SWOT analysis
        4. Recent developments
        5. strategies
        6. financials (based on availability)
      10. Bayer AG
        1. Overview
        2. Products
        3. SWOT analysis
        4. Recent developments
        5. strategies
        6. financials (based on availability)
Read Less

Figure 1: U.S. Diabetes Drugs Market Revenue Breakdown (USD billion, %) by Drug Class, 2022 & 2030

Figure 2: U.S. Diabetes Drugs Market Value Share (%), by Drug Class, 2022 & 2030

Figure 3: U.S. Diabetes Drugs Market Value Share (%), by Diabetes Type, 2022 & 2030

Figure 4: U.S. Diabetes Drugs Market Value Share (%), by Route of Administration, 2022 & 2030

Figure 5: U.S. Diabetes Drugs Market Value Share (%), by Distribution Channel, 2022 & 2030

Figure 6: U.S. Diabetes Drugs Market Share (%), By Company, 2022

Table 1: U.S. Diabetes Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2019–2030

Table 2: U.S. Diabetes Drugs Market Revenue (USD billion) Forecast, by Diabetes Type, 2019–2030

Table 3: U.S. Diabetes Drugs Market Revenue (USD billion) Forecast, by Route of Administration, 2019–2030

Table 4: U.S. Diabetes Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2019–2030

U.S. Diabetes Drugs Market
  • 2019-2030
  • 2022
  • 2019-2021
  • 80
Download Free Sample

    man icon
    Mail icon
    Captcha refresh
Growth Advisory Services
    How can we help you uncover new opportunities and scale faster?
Clients
3M
Toshiba
Fresenius
Johnson
Siemens
Abbot
Allergan
American Medical Association
Becton, Dickinson and Company
Bristol-Myers Squibb Company
Henry Schein
Mckesson
Mindray
National Institutes of Health (NIH)
Nihon Kohden
Olympus
Quest Diagnostics
Sanofi
Smith & Nephew
Straumann

Related Reports